| abstract |
Induction of tumor immunity by a variant of folate binding protein. The present invention relates to various antigen variants, including folate-binding protein epitopes, as compositions related to immunogenicity arising in tumors in individuals. This variant is effective in inducing cytotoxic T lymphocytes, but is preferably susceptible to silencing by removal (eg, by apoptosis or as unresponsive) It is not up to the level of anergy. In one aspect, the invention provides SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 in a pharmaceutically acceptable excipient. , SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or a combination thereof, an antigen comprising a folate binding protein epitope is provided as a composition of matter. [Selection figure] None |